Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy
Protein Degradation Specialist Gets $1bn Up Front
Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy 
